Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality -5% Improvement Relative Risk ICU admission 31% Oxygen therapy 40% Time to improvement 64% Improvement 34% Time to discharge 27% Discharge 8% c19nitazoxanide.com Rocco et al. NCT04561219 Nitazoxanide RCT LATE TREATMENT Favors nitazoxanide Favors control
Rocco, 405 patient nitazoxanide late treatment RCT: 5% higher mortality [p=0.95], 31% lower ICU admission [p=0.18], 40% lower need for oxygen therapy [p=0.06], and 64% faster improvement [p<0.0001] https://c19p.org/rocco2
copied to clipboard
Nitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Rocco et al., Frontiers in Medicine, doi:10.3389/fmed.2022.844728, NCT04561219 (history)
13 Apr 2022    Source   PDF   Share   Tweet
RCT late stage patients with COVID-19 pneumonia, 202 treated with nitazoxanide and 203 placebo patients, showing improved recovery, but no significant difference in mortality.
risk of death, 4.9% higher, RR 1.05, p = 0.94, treatment 6 of 202 (3.0%), control 5 of 203 (2.5%), adjusted per study, odds ratio converted to relative risk, multivariable, day 14.
risk of ICU admission, 30.5% lower, RR 0.69, p = 0.18, treatment 20 of 202 (9.9%), control 30 of 203 (14.8%), NNT 21, adjusted per study, odds ratio converted to relative risk, multivariable, day 14.
risk of oxygen therapy, 39.7% lower, RR 0.60, p = 0.06, treatment 22 of 202 (10.9%), control 33 of 203 (16.3%), NNT 19, adjusted per study, odds ratio converted to relative risk, multivariable, day 14.
time to improvement, 63.6% lower, HR 0.36, p < 0.001, treatment 202, control 203, inverted to make RR<1 favor treatment, Kaplan–Meier.
improvement, 34.2% better, OR 0.66, p = 0.14, treatment 202, control 203, adjusted per study, inverted to make OR<1 favor treatment, multivariable, day 14, RR approximated with OR.
time to discharge, 27.0% lower, HR 0.73, p = 0.004, treatment 202, control 203, inverted to make RR<1 favor treatment, Kaplan–Meier.
discharge, 8.3% lower, OR 0.92, p = 0.82, treatment 202, control 203, adjusted per study, inverted to make OR<1 favor treatment, multivariable, day 14, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rocco et al., 13 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, peer-reviewed, median age 56.0, 37 authors, study period 20 April, 2020 - 2 October, 2020, trial NCT04561219 (history).
Contact: prmrocco@biof.ufrj.br.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit